Tower Research Capital LLC (Trc) Unicycive Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 10,888 shares of UNCY stock, worth $6,206. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,888
Previous 22,782
52.21%
Holding current value
$6,206
Previous $9,000
11.11%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding UNCY
# of Institutions
32Shares Held
61.7MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT11MShares$6.26 Million5.72% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT10.4MShares$5.92 Million0.41% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$5.7 Million1.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA9.97MShares$5.68 Million1.54% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$2.89 Million0.53% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $8.58M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...